BSX

Stryker (SYK) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 29. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. This medical device maker is expected to post quarterly earnings of $3.56 per share in its upcoming report, which represents a year-over-year change of +11.6%. Revenues are expected to be $6.58 billion, up 8.6% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 0.8% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). For Stryker, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -0.44%. On the other hand, the stock currently carries a Zacks Rank of #4. So, this combination makes it difficult to conclusively predict that Stryker will beat the consensus EPS estimate. While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Stryker would post earnings of $3.46 per share when it actually produced earnings of $3.69, delivering a surprise of +6.65%. Over the last four quarters, the company has beaten consensus EPS estimates three times. An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Stryker doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Another stock from the Zacks Medical - Products industry, Boston Scientific (BSX), is soon expected to post earnings of $0.76 per share for the quarter ended September 2026. This estimate indicates a year-over-year change of +1.3%. Revenues for the quarter are expected to be $5.17 billion, up 2.1% from the year-ago quarter. The consensus EPS estimate for Boston Scientific has been revised 0.5% lower over the last 30 days to the current level. However, a lower Most Accurate Estimate has resulted in an Earnings ESP of -1.44%. When combined with a Zacks Rank of #4 (Sell), this Earnings ESP makes it difficult to conclusively predict that Boston Scientific will beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Stryker Corporation (SYK) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Boston Scientific Corporation BSX is slated to report third-quarter 2026 results on Oct. 28, before the market opens. The renowned medical device manufacturer posted earnings per share (EPS) of 86 cents in the last reported quarter, which surpassed the Zacks Consensus Estimate by 3.61%. The company topped earnings estimates in three of the trailing four quarters and broke even once, the average surprise being 2.95%. For the third quarter of 2026, the Zacks Consensus Estimate for Boston Scientific's revenues is pegged at $5.17 billion, indicating an increase of 2.1% from the year-ago reported figure. The Zacks Consensus Estimate for the company's third-quarter EPS suggests a 1.3% rise to 76 cents. The estimate has dropped 5% in the past 30 days. Let's briefly review the company's performance leading up to this announcement. In the third quarter of 2026, the segment may have contributed due to continued strength in Endoscopy and Neuromodulation. Endoscopy sales are likely to have gained from the biliary franchise, led by the AXIOS Stent and Delivery System, and the core gastrointestinal (GI) franchise. Boston Scientific also secured FDA clearance for RIVOS, a first-of-its-kind single device designed to consolidate multiple exchanges, allowing physicians to streamline procedural steps while performing endoscopic ultrasound biliary drainage. Initial cases had received positive feedback. Neuromodulation is likely to have benefited from the strength of its comprehensive pain portfolio, led by the Intracept Intraosseous Nerve Ablation System. The acquired Nalu Medical may have provided another quarter of solid sales contribution, with integration efforts continuing. In the brain franchise, Boston Scientific's global growth may have been favorably supported by the continued adoption of the Cartesia X leads and accelerating uptake of the Illumina 3D programming algorithm in the United States. Boston Scientific Corporation price-eps-surprise | Boston Scientific Corporation Quote Meanwhile, similar to the previous quarter, Urology may have faced continued headwinds from weakness in the stone franchise due to volume-based procurement in China and commercial disruption in sacral neuromodulation. The Zacks Consensus Estimate projects MedSurg revenues to increase 1.6% year over year in the third quarter. In the third quarter of 2026, Boston Scientific may have faced continued weakness in two historically strong Cardiovascular businesses. During the July earnings call, management lowered its full-year organic revenue and profitability outlook, citing a more challenging second half of 2026 than previously expected. WATCHMAN sales were hurt by an unexpected slowdown in the U.S. market, as compounding clinical evidence impacted referral patterns. In Electrophysiology ("EP"), the level of competitive share movement in the U.S. market was greater than anticipated. The Cardiac Rhythm Management ("CRM") business may remain a drag on the quarter's results, reflecting continued competitive pressures and gaps within the product portfolio. Weakness across its low-voltage and high-voltage businesses is likely to have persisted. On a positive note, strength across the company's broad diagnostic portfolio may have helped offset some of the pressures. Boston Scientific is also expected to have seen sustained momentum in its Interventional Cardiology business, driven by continued strength in DCB, imaging and complex PCI. Vascular Therapies results may benefit from broader adoption of Varithena and the drug-eluting portfolio. Following strong reception of the SEISMIQ IVL device for its clinical differentiation, the company is likely to have continued to ramp up its supply. Interventional Oncology and Embolization is also expected to have delivered strong global growth, aided by demand for its broad range of technologies. According to the Zacks Consensus Estimate, Cardiovascular revenues are expected to see a 0.7% decline from the prior-year period. Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see. Earnings ESP: Boston Scientific has an Earnings ESP of -3.63%. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank stocks here. Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time: Phibro Animal Health PAHC has an Earnings ESP of +2.10% and a Zacks Rank #1. The company is expected to release first-quarter fiscal 2027 results soon. PAHC's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 18.4%. The Zacks Consensus Estimate for the company's first-quarter EPS indicates an increase of 8.2% from the year-ago quarter's figure. IDEXX Laboratories IDXX has an Earnings ESP of +0.59% and a Zacks Rank #2. The company is slated to release third-quarter 2026 results on Nov. 2. IDXX's earnings beat estimates in each of the trailing four quarters, the average surprise being 5.7%. The Zacks Consensus Estimate for the company's third-quarter EPS implies a jump of 9.1% from the year-ago quarter's figure. Becton, Dickinson and Company BDX, or BD, has an Earnings ESP of +3.28% and a Zacks Rank #2. The company will release its fourth-quarter fiscal 2026 results on Nov. 5. BD's earnings surpassed estimates in each of the trailing four quarters, the average surprise being 2.94%. The Zacks Consensus Estimate for the company's fourth-quarter EPS calls for a rise of 2.5% from the year-ago quarter's figure. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report Phibro Animal Health Corporation (PAHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Boston Scientific (BSX) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on October 28. On the other hand, if they miss, the stock may move lower. While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise. This medical device manufacturer is expected to post quarterly earnings of $0.76 per share in its upcoming report, which represents a year-over-year change of +1.3%. Revenues are expected to be $5.17 billion, up 2.1% from the year-ago quarter. The consensus EPS estimate for the quarter has been revised 0.51% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Price, Consensus and EPS Surprise Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). For Boston Scientific, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -3.63%. On the other hand, the stock currently carries a Zacks Rank of #4. So, this combination makes it difficult to conclusively predict that Boston Scientific will beat the consensus EPS estimate. Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Boston Scientific would post earnings of $0.83 per share when it actually produced earnings of $0.86, delivering a surprise of +3.61%. Over the last four quarters, the company has beaten consensus EPS estimates three times. An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Boston Scientific doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Abbott Laboratories (NYSE:ABT) is scheduled to report its earnings on Wednesday, October 21, 2026. The company has a market value of about $181.1 billion. Over the last twelve months it generated $46.6 billion in revenue and $7.3 billion in operating profit, with net income of $5.4 billion. The reaction will turn on how the results and guidance land against expectations. Before the release, it helps to know how the stock has behaved after previous reports, and whether an early move has tended to carry on. See the earnings reaction history of all stocks How Often Has Abbott Laboratories Stock Risen After Earnings? Some observations on one-day (1D) post-earnings returns, measured from the last close before each release: - There are 19 earnings releases in the last five years, with 8 positive and 11 negative one-day (1D) returns. Positive 1D returns were seen 42% of the time. - Over the last three years that share falls to 36%, across 11 releases. - The median of the 8 positive 1D returns is 3.2%, and the median of the 11 negative ones is -3.0%. - The largest one-day reactions were 10.7% and -10.0%. The table below shows the 1D, 5-day (5D) and 21-day (21D) returns after each release, followed by summary statistics. Earnings Date | 1D | 5D | 21D 7/16/2026 | 10.7% | 12.7% | 24.6% 4/16/2026 | -6.0% | -9.7% | -16.4% 1/22/2026 | -10.0% | -12.2% | -7.1% 10/15/2025 | -2.4% | -3.9% | -2.9% 7/17/2025 | -8.5% | -4.5% | -1.9% 4/16/2025 | 2.8% | 2.9% | 5.6% 1/22/2025 | 0.8% | 9.1% | 14.0% 10/16/2024 | 1.5% | 0.1% | -0.3% 7/18/2024 | -4.4% | 2.5% | 6.0% 4/17/2024 | -3.0% | -1.5% | -4.2% 1/24/2024 | -2.8% | -0.5% | 4.4% 10/18/2023 | 3.7% | 2.9% | 6.4% 7/20/2023 | 4.2% | 6.3% | -2.2% 4/19/2023 | 7.8% | 5.6% | 4.5% 1/25/2023 | -1.4% | -1.8% | -8.9% 10/19/2022 | -6.5% | -6.7% | -1.3% 7/20/2022 | -1.5% | -0.8% | 0.6% 4/20/2022 | 2.2% | -2.5% | -6.0% 1/26/2022 | -2.6% | 3.2% | -3.7% Statistic | 1D | 5D | 21D # Positive | 8 | 9 | 8 # Negative | 11 | 10 | 11 Median Positive | 3.2% | 3.2% | 5.8% Median Negative | -3.0% | -3.2% | -3.7% Max Positive | 10.7% | 12.7% | 24.6% Max Negative | -10.0% | -12.2% | -16.4% Do Early Post-Earnings Moves Continue? Another approach is to wait for the initial reaction and ask whether it tends to continue. The table below shows the correlation between the 1D return and the return over the following 5 and 21 trading days, and between the 5D return and the following 21 trading days. A value near 1 means the first move has tended to continue; near -1, to reverse; near 0, no consistent pattern. Over five years, none of these correlations is strong enough to trade on: all are below 0.40. Over the last three years, the 5D return and the next 21 days have moved together more (0.43), but that rests on only 11 releases. History | 1D vs next 5D | 1D vs next 21D | 5D vs next 21D 5 Years | -0.15 | -0.05 | 0.06 3 Years | 0.15 | 0.25 | 0.43 Do Peers That Report First Offer A Clue? Johnson & Johnson (JNJ) usually reports a few days before Abbott Laboratories, and has already reported this season. The table compares each peer's one-day reaction to its own earnings with Abbott Laboratories' one-day reaction to the report that followed. The correlation is -0.53; the closer to 1, the more the peer's reaction has foreshadowed Abbott Laboratories', and a negative value means it has tended to point the other way. ABT Earnings Date | ABT 1D | JNJ 1D 7/16/2026 | 10.7% | -2.7% 4/16/2026 | -6.0% | 0.9% 1/22/2026 | -10.0% | -0.1% 10/15/2025 | -2.4% | -0.03% 7/17/2025 | -8.5% | 6.2% 4/16/2025 | 2.8% | -0.5% 10/16/2024 | 1.5% | 1.5% 7/18/2024 | -4.4% | 3.7% 1/24/2024 | -2.8% | -1.6% 10/18/2023 | 3.7% | -0.9% 4/19/2023 | 7.8% | -2.8% 1/25/2023 | -1.4% | n/a 10/19/2022 | -6.5% | -0.3% 7/20/2022 | -1.5% | -1.5% 4/20/2022 | 2.2% | 3.1% 1/26/2022 | -2.6% | 2.9% Correlation | - | -0.53 Trading around earnings is a bet on a single event. If you want upside with a smoother ride than an individual stock such as ABT can offer, consider the Trefis High Quality (HQ) Portfolio: about 30 stocks selected for consistent cash generation, strong margins and resilient balance sheets, with a track record of outperforming a benchmark that combines the S&P 500, the S&P MidCap 400, and the Russell 2000.

Johnson & Johnson's JNJ shares declined around 5.8% on Tuesday in response to its third-quarter 2026 results. While earnings beat estimates, J&J's sales slightly fell short of expectations. Although the company increased its full-year outlook, weaker-than-expected performance in its MedTech business weighed on investor sentiment while Innovative Medicine continued to outperform. The biggest concern was sluggish growth in the MedTech segment, where sales increased just 2.5% to $8.64 billion, compared with 7.7% growth in Innovative Medicine. Management acknowledged that MedTech's performance fell below internal expectations, particularly in international markets and at Abiomed. Abiomed sales declined 2.3% in the third quarter due to lower procedure volumes and more cautious physician use of Impella following a U.K. clinical trial that questioned its benefit in certain high-risk procedures. Changes in patient selection weighed on demand, creating uncertainty around the business's recovery. Internationally, expanded volume-based procurement in China, the impact of J&J's surgery transformation program, and Middle East disruptions to tender timing and ordering patterns hurt sales in the Surgery segment. Competitive pressure in pulsed field ablation, particularly in Asia-Pacific, hurt electrophysiology growth. In the Innovative Medicine segment, sales of key cancer drugs Darzalex, Erleada and Imbruvica fell short of expectations. Share gains and market growth for Darzalex and Erleada were partially offset by outside U.S. pricing headwinds for Darzalex and unfavorable patient mix for Erleada. The loss of exclusivity of blockbuster immunology drug Stelara reduced Innovative Medicine's operational growth by approximately 690 basis points. Earnings performance also offered less reassurance than revenue growth. Total sales rose 5.9% to $25.4 billion, but adjusted earnings per share declined 7.5% to $2.59. The company said the Firefly Bio acquisition and Sail Biomedicines collaboration affected adjusted earnings. These investments may strengthen its pipeline over time, but their immediate costs reduced profitability. Despite these headwinds, J&J continued to expect accelerated growth in 2026. Strength in Innovative Medicine is expected to persist, while MedTech performance is projected to improve in the fourth quarter, supported by a stable procedure environment and new product launches. Growth is expected to strengthen further in 2027. J&J also expects Surgery to return to growth in the fourth quarter, driven by continued U.S. growth and an acceleration in EMEA. J&J is confident about achieving its target of generating more than $100 billion in revenues in 2026, with $74.8 billion already generated in the first three quarters. It expects sales growth to be even better in 2027, with a "line of sight" to double-digit growth by the end of the decade. J&J's MedTech unit faces strong competition from several major players in the medical device industry, such as Medtronic MDT, Abbott, Stryker SYK and Boston Scientific BSX. While Medtronic has a strong presence in cardiovascular, neuroscience and surgical technologies, Stryker is a major player in orthopedics and surgical equipment. Boston Scientific markets products for cardiovascular, endoscopy, urology and neuromodulation. Abbott is known for its medical devices across cardiovascular, diagnostics and diabetes care. J&J's shares have outperformed the industry so far this year. The stock has risen 20.1% this year compared with 13.0% appreciation of the industry. Image Source: Zacks Investment Research From a valuation standpoint, J&J is slightly expensive. Going by the price/earnings ratio, the company's shares currently trade at 20.75 forward earnings, higher than 18.33 for the industry. The stock is also trading above its five-year mean of 15.65. Image Source: Zacks Investment Research The Zacks Consensus Estimate for 2026 earnings has declined from $11.32 to $11.08 over the past seven days, while that for 2027 earnings has declined from $12.39 per share to $12.13 over the same time frame. Image Source: Zacks Investment Research J&J has a Zacks Rank #4 (Sell) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Johnson & Johnson (JNJ) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report Stryker Corporation (SYK) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Valued at a market cap of $63.5 billion, Boston Scientific Corporation (BSX) is a global medical technology company headquartered in Marlborough, Massachusetts. It develops, manufactures, and markets innovative medical devices used to diagnose and treat a wide range of medical conditions. Its products support minimally invasive procedures across cardiovascular care, electrophysiology, neuromodulation, endoscopy, urology, and oncology. The medtech titan is expected to announce its fiscal Q3 earnings before the market opens on Wednesday, Oct. 28. Before this event, analysts expect this healthcare company to report a profit of $0.76 per share, up 1.3% from $0.75 per share in the year-ago quarter. The company has topped or met Wall Street's bottom-line estimates in each of the last four quarters. - Why It's Time to Load Up on Marvell Stock - Dear Accenture Stock Fans, Mark Your Calendars for Oct. 14 - Dear Nvidia Stock Fans, Mark Your Calendars for October 13 - Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For the current fiscal year, ending in December, analysts expect BSX to report a profit of $3.25 per share, up 6.2% from $3.06 per share in fiscal 2025. Furthermore, its EPS is expected to grow 3.4% year over year to $3.36 in fiscal 2027. Shares of BSX have declined 54.4% over the past 52 weeks, notably underperforming both the S&P 500 Index's ($SPX) 17.3% return and the State Street Health Care Select Sector SPDR ETF's (XLV) 19.5% rise over the same time period. Boston Scientific shares have lagged the broader market over the past year as slowing growth in key product lines and repeated earnings outlook cuts have shaken investor confidence. The company lowered its fiscal 2026 profit forecast in July, citing weaker-than-expected demand for its WATCHMAN heart implant and intensifying competition in its U.S. electrophysiology business, which has contributed to market share losses. Adding to the pressure, a September cybersecurity incident disrupted manufacturing and global order shipments, prompting Boston Scientific to warn that it was unlikely to meet its previously issued third-quarter and full-year sales and adjusted earnings forecasts. Wall Street analysts are reasonably optimistic about BSX's stock, with an overall "Moderate Buy" rating. Among 30 analysts covering the stock, 19 recommend "Strong Buy," four suggest "Moderate Buy," six indicate "Hold," and the remaining analyst affirms a "Strong Sell." The mean price target for BSX is $56.92, indicating a 31.4% potential upside from the current levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com

Looking back on medical devices & supplies - diversified stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Boston Scientific (NYSE:BSX) and its peers. The medical devices industry operates a business model that balances steady demand with significant investments in innovation and regulatory compliance. The industry benefits from recurring revenue streams tied to consumables, maintenance services, and incremental upgrades to the latest technologies. However, the capital-intensive nature of product development, coupled with lengthy regulatory pathways and the need for clinical validation, can weigh on profitability and timelines. In addition, there are constant pricing pressures from healthcare systems and insurers maximizing cost efficiency. Over the next several years, one tailwind is demographic–aging populations means rising chronic disease rates that drive greater demand for medical interventions and monitoring solutions. Advances in digital health, such as remote patient monitoring and smart devices, are also expected to unlock new demand by shortening upgrade cycles. On the other hand, the industry faces headwinds from pricing and reimbursement pressures as healthcare providers increasingly adopt value-based care models. Additionally, the integration of cybersecurity for connected devices adds further risk and complexity for device manufacturers. The 6 medical devices & supplies - diversified stocks we track reported a satisfactory Q2. As a group, revenues beat analysts’ consensus estimates by 2% while next quarter’s revenue guidance was 2.2% below. In light of this news, share prices of the companies have held steady. On average, they are relatively unchanged since the latest earnings results. Founded in 1979 with a mission to advance less-invasive medicine, Boston Scientific (NYSE:BSX) develops and manufactures medical devices used in minimally invasive procedures across cardiovascular, urological, neurological, and gastrointestinal specialties. Boston Scientific reported revenues of $5.44 billion, up 7.5% year on year. This print exceeded analysts’ expectations by 1.5%. Despite the top-line beat, it was still a softer quarter for the company with revenue guidance for next quarter missing analysts’ expectations significantly and a miss of analysts’ full-year EPS guidance estimates. "Our team delivered a solid quarter while continuing to navigate a dynamic environment," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. The market seems disappointed with the results as the stock is down 6.4% since reporting and currently trades at $43.12. Is now the time to buy Boston Scientific? Access our full analysis of the earnings results here, it’s free. With a history dating back to 1931 and products used in over 100 countries, Baxter International (NYSE:BAX) provides essential healthcare products including dialysis therapies, IV solutions, infusion systems, surgical products, and patient monitoring technologies to hospitals and clinics worldwide. Baxter reported revenues of $2.96 billion, up 5.3% year on year, outperforming analysts’ expectations by 6%. The business had an incredible quarter with a beat of analysts’ full-year EPS guidance estimates. Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 3.5% since reporting. It currently trades at $23.91. Is now the time to buy Baxter? Access our full analysis of the earnings results here, it’s free. With a history dating back to 1958 and a portfolio spanning two distinct healthcare segments, Cooper Companies (NASDAQ:COO) develops and manufactures medical devices focused on vision care through contact lenses and women's health including fertility products and services. CooperCompanies reported revenues of $1.07 billion, flat year on year, falling short of analysts’ expectations by 2.9%. It was a softer quarter as it posted a significant miss of analysts’ organic revenue and full-year EPS guidance estimates. CooperCompanies delivered the weakest performance against analyst estimates and weakest full-year guidance update in the group. As expected, the stock is down 15% since the results and currently trades at $53.93. Read our full analysis of CooperCompanies’s results here. With over 150 million patients impacted annually through its innovative healthcare technologies, Stryker (NYSE:SYK) develops and manufactures advanced medical devices and equipment across orthopedics, surgical tools, neurotechnology, and patient care solutions. Stryker reported revenues of $6.59 billion, up 9.4% year on year. This print met analysts’ expectations. Taking a step back, it was a mixed quarter as it also logged a beat of analysts’ EPS estimates but organic revenue in line with analysts’ estimates. The stock is down 20.6% since reporting and currently trades at $276.26. Read our full, actionable report on Stryker here, it’s free. With roots dating back to 1888 when founder Dr. Wallace Abbott began producing precise, dosage-form medications, Abbott Laboratories (NYSE:ABT) develops and sells a diverse range of healthcare products including medical devices, diagnostics, nutrition products, and branded generic pharmaceuticals. Abbott Laboratories reported revenues of $12.59 billion, up 13% year on year. This result beat analysts’ expectations by 1.1%. Overall, it was a satisfactory quarter as it also produced a narrow beat of analysts’ full-year EPS guidance estimates. Abbott Laboratories scored the fastest revenue growth of the whole group. The stock is up 14.5% since reporting and currently trades at $102.25. Read our full, actionable report on Abbott Laboratories here, it’s free. Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership. Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products. By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals. Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.

The company expects to recover some impacted revenue as it works through order backlogs, but said the full financial impact remains uncertain. Boston Scientific has resumed certain operations, but the timeline for a full operational recovery is not yet known. The firm previously expected third-quarter sales to grow between 3% and 5% of its Q3 2025 sales of $5.07 billion. Boston Scientific (BSX) said a cyberattack that disrupted its global operations last month is expected to materially impact its third-quarter and full-year 2026 results, making it unlikely to meet its previously forecast net sales growth and adjusted earnings per share (EPS) guidance ranges. The medical-device maker first identified the incident on August 25. Unauthorized activity caused a network outage that limited access to operating systems and business applications, disrupting manufacturing and the processing and shipment of customer orders. See what 10M+ investors are talking about. Get the Stocktwits Daily Rip for what retail is watching right now, free to your inbox At the time of writing, BSX shares were trading over 5% lower, having declined around 9% since reporting the incident. Boston Scientific previously expected third-quarter (Q3) 2025 sales to grow between 3% and 5% from its Q3 2025 sales of $5.07 billion. Adjusted earnings were expected to be between $0.80 and $0.82 per share, surpassing the $0.75 per share in the previous corresponding period. For full year 2026, the company forecast sales growth of 5.5% to 6.5% from $20.07 billion in full year 2025, and adjusted earnings of $3.28 to $3.32 per share, versus $3.06 per share last year. The company now expects to fall short of these ranges because of the cyberattack. On Tuesday, Boston Scientific said its distribution network has been substantially restored, with major centers processing and shipping orders at or above normal levels. Sterilization facilities are also operational, while manufacturing has resumed across most global facilities. However, it said the timeline for a full operational recovery is not yet known. The company expects to recover some impacted revenue as it works through order backlogs, but said the full financial impact remains uncertain. It plans to provide updated guidance for 2026 with its third-quarter results on Oct. 28, 2026. Retail sentiment surrounding BE on Stocktwits changed to ‘neutral’ from ‘bearish’ over the past 24 hours. One user said the stock is “primed to retest the lows.” However, another user believes that the stock may have already bottomed out and will likely climb back over $50 by next week. The stock has been under heavy selling pressure so far this year, declining more than 52%. Also read: Bloom Energy’s S&P 500 Entry Could Bring A New Wave Of Buyers, Says Clear Street — Projects 20% Upside In BE Stock For updates and corrections, email newsroom[at]stocktwits[dot]com. Arnab Paul has no position in any of the stocks mentioned in this article. StockTwits' news team content is for informational purposes only and is not intended as investment advice. For more, see our editorial policy. This article was originally published on StockTwits. Related: QCOM Stock Extends Gains Overnight: Analyst Says Amazon AI Deal 'Changes Calculus For Qualcomm' QCOM Stock Extends Gains Overnight: Analyst Says Amazon AI Deal 'Changes Calculus For Qualcomm' HOOD Stock Ticks Up Overnight — Why This Analyst Sees Upside Of Over 19% From Here

It has been about a month since the last earnings report for Boston Scientific (BSX). Shares have added about 1.5% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Boston Scientific due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers. Boston Scientific reported second-quarter 2026 adjusted earnings of 86 cents per share, up 14.7% year over year. The figure beat the Zacks Consensus Estimate by 3.6%. Revenues rose 7.5% on a reported basis to $5.44 billion and surpassed the consensus estimate by 1.1%. Cardiovascular growth, double-digit gains in Asia-Pacific (APAC) and Latin America and Canada (LACA) and strong Neuromodulation sales supported the quarter. Cardiovascular revenues totaled $3.62 billion, increasing 8.3% on a reported basis and 7.8% on an operational and organic basis. The segment generated roughly two-thirds of Boston Scientific’s quarterly revenues and remained the primary growth contributor. MedSurg revenues rose 5.9% to $1.82 billion, with operational and organic growth of 5.4%. Within the segment, Endoscopy sales increased 7.6% to $793 million, while Neuromodulation revenues climbed 12.7% to $341 million. Urology revenues advanced 1.1% to $684 million, marking the slowest growth among the company’s reported businesses. U.S. revenues increased 6.2% to $3.43 billion. The domestic market remained Boston Scientific’s largest region, generating nearly 63% of consolidated sales. APAC revenues rose 11.2% to $878 million, while LACA sales surged 22.4% to $206 million. LACA operational growth was 16.2%. Europe, Middle East and Africa (“EMEA”) revenues increased 6.1% to $932 million, although operational growth was lower at 4.2% due to currency effects. The gross margin expanded approximately 306 basis points (bps) year over year to 70.7%. The cost of products sold declined 2.6% to $1.59 billion in the reported quarter. Selling, general and administrative expenses rose 5.1% to $1.80 billion. Research and development expenses increased 5.3% to $554 million, while royalty expenses plunged 14.3% to $12 million. Adjusted operating margin expanded approximately 71 bps to 28.4%. Boston Scientific presented data from the FRACTURE trial of the SEISMIQ 4CE coronary intravascular lithotripsy catheter. The study met its primary endpoints, demonstrating procedural success and high freedom from major adverse cardiac events at 30 days. The AVANT GUARD study also met its safety and effectiveness endpoints. FARAPULSE pulsed field ablation demonstrated statistical superiority over anti-arrhythmic drugs in patients with persistent atrial fibrillation who had not received prior treatment for the condition. The company invested $1.5 billion in MiRus LLC for an approximately 34% equity stake and an exclusive option to acquire its transcatheter aortic valve replacement business. MiRus is developing the investigational SIEGEL balloon-expandable TAVR system. BSX also completed its previously announced $2 billion accelerated share repurchase program. The transaction resulted in the repurchase of approximately 40 million shares, reducing the company’s outstanding share base. Boston Scientific now expects reported sales growth of 5.5-6.5%, down from its prior forecast of 7-8.5%. Organic sales growth is now projected at 5-6% compared with the earlier range of 6.5-8%. The company also reduced its full-year adjusted earnings forecast to $3.28-$3.32 per share from the earlier $3.34-$3.41. For the third quarter, management forecasts reported and organic sales growth of 3-5%. Adjusted earnings are expected between 80 cents and 82 cents per share. In the past month, investors have witnessed a downward trend in estimates revision. Currently, Boston Scientific has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. However, the stock has a grade of C on the value side, putting it in the middle 20% for this investment strategy. Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in. Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Boston Scientific has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months. Boston Scientific belongs to the Zacks Medical - Products industry. Another stock from the same industry, Royal Philips (PHG), has gained 1.8% over the past month. More than a month has passed since the company reported results for the quarter ended June 2026. Philips reported revenues of $5.07 billion in the last reported quarter, representing a year-over-year change of +3%. EPS of $0.57 for the same period compares with $0.41 a year ago. Philips is expected to post break-even earnings per share for the current quarter, representing a year-over-year change of 0%. Over the last 30 days, the Zacks Consensus Estimate has changed 0%. The overall direction and magnitude of estimate revisions translate into a Zacks Rank #3 (Hold) for Philips. Also, the stock has a VGM Score of A. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Koninklijke Philips N.V. (PHG) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Medtronic plc MDT is slated to report its first-quarter fiscal 2027 results on Sept. 1, before the opening bell. The Zacks Consensus Estimate for the company’s first-quarter earnings per share (EPS) suggests 10.3% year-over-year growth to $1.39. The estimate has remained constant in the past 60 days. The consensus mark for first-quarter revenues currently stands at $9.47 billion, implying a 10.4% increase over the prior-year period. Image Source: Zacks Investment Research Medtronic has a solid earnings surprise history, beating estimates in each of the past four quarters, with an average surprise of 2.3%. Image Source: Zacks Investment Research Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates. This is not the case here, as you can see below. Earnings ESP: Medtronic has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #3. You can see the complete list of today’s Zacks Rank #1 stocks here. The segment is likely to have witnessed a solid performance across both U.S. and international markets. Within this, Cardiac Ablation Solutions (“CAS”) is expected to have remained the key growth driver, supported by momentum in the pulsed field ablation portfolio, which grew 145% in the previous quarter. The launch of the Sphere-9 catheter in Japan may have also strengthened Medtronic’s position in the region. The company has also begun the global rollout of Prism-2, its next-generation mapping software, which offers improved navigation through hybrid impedance and magnetic mapping. In June 2026, Medtronic announced strategic investments in two privately held companies focused on the development of intracardiac echocardiography (ICE) catheter technologies, which may have provided an additional boost to revenues. Cardiac Rhythm Management may also have contributed, driven by Micra leadless pacemakers, Aurora implantable cardioverter defibrillator (EV-ICD) system and the SelectSecure 3830 lead. In Structural Heart, revenues are expected to have benefited from continued international strength as well as stabilizing U.S. procedure volumes. Growth in the Symplicity Spyral renal denervation system, guide catheters and balloons, as well as Endovenous growth in Peripheral Vascular Health, may have boosted Coronary & Peripheral Vascular sales. The Zacks Consensus Estimate implies Cardiovascular revenues will increase 15.2% year over year. Medtronic continues to invest across its Neuroscience portfolio to advance pipeline innovation and support long-term growth. Within this, Cranial and Spinal Technologies results in the fiscal first quarter may benefit from the continued adoption of the AiBLE ecosystem, with Core Spine and Neurosurgery also likely contributing to growth. The commercial rollout of the Stealth AXiS surgical system may have further advanced. In June, Medtronic received the CE mark for the ear, nose and throat indications, expanding the platform’s reach. Neuromodulation performance is expected to have been led by the Inceptiv closed-loop spinal cord stimulator, the Percept RC neurostimulator with BrainSense technology, and Interventional products. Medtronic completed two acquisitions within this business. The Scientia Vascular acquisition in June adds a portfolio of guidewires and catheters to its existing neurovascular product lineup, while the July acquisition of SPR Therapeutics, Inc. (SPR) expands its ability to serve patients across the pain care continuum. The Zacks Consensus Estimate expects Neuroscience revenues to grow 10.7% year over year. In the fiscal first quarter, MedSurg performance is expected to have been driven by solid growth in Advanced Energy and Wound Management, alongside higher contribution from the Hugo robotic-assisted surgery system. However, similar to recent trends, continued pressure on U.S. bariatric surgery procedure volumes may have partially offset this growth. Endoscopy is likely to have been a growth driver, with sales benefiting from strong adoption of Endoflip in the United States and Western Europe, as well as from U.S. market share gains of the Nexpowder hemostasis system. Acute Care and Monitoring may have gained from strength in Nellcor pulse oximetry, respiratory and airways and in perioperative. The Zacks Consensus Estimate for MedSurg’s revenues suggests a 7.6% year-over-year increase. MiniMed, Medtronic’s diabetes business, completed an initial public offering in March, with approximately 10% of its ownership sold and its shares beginning to trade on the Nasdaq Global Select Market. Medtronic continues to hold approximately 90% ownership in MiniMed. In the first quarter of fiscal 2027, the business is likely to have witnessed robust international contributions from the continued adoption of the MiniMed 780G Automated Insulin Delivery (AID) system, including the Simplera Sync and Guardian 4 continuous glucose monitoring sensors and Extended Infusion Sets. U.S. momentum may also have continued following the late-2025 launches of the Simplera Sync and Abbott’s Instinct sensors. The quarter also saw several key developments. MiniMed announced the commercial availability of MiniMed Flex, its smallest app-controlled insulin pump powered by the advanced SmartGuard algorithm. The system is FDA cleared for people with type 1 diabetes aged 7 years and older, as well as adults aged 18 years and older with insulin-requiring type 2 diabetes and is paired with the Simplera Sync sensor. MiniMed Flex is also now available to Medicare and Medicare Advantage beneficiaries. MiniMed launched the MiniMed 780G system integrated with Abbott’s Instinct sensor and the MiniMed Go system with the Instinct Go sensor in Europe. Together, these developments are expected to have strongly boosted overall revenues in the quarter. The Zacks Consensus Estimate suggests Diabetes revenues will grow 15.1% year over year. Over the past three months, Medtronic shares have outperformed the industry and the broader Medical sector. Image Source: Zacks Investment Research The stock has also fared better than major peers like Boston Scientific BSX, whose shares fell 2%, while Edward Lifesciences EW gained 4.8%. Boston Scientific’s second-quarter 2026 revenues and EPS surpassed the Zacks Consensus Estimate by 1.1% and 3.6%, respectively. However, the company lowered its 2026 sales and earnings outlook after slower WATCHMAN demand, U.S. electrophysiology share losses and limited operating leverage weakened near-term visibility. Meanwhile, Edwards’ second-quarter revenues and EPS topped the consensus mark by 2.4% and 6.8%, respectively. Medtronic trades at a forward five-year Price/Earnings (P/E) of 14.98X, lower than its median of 15.73X and the industry average of 17.74X. Image Source: Zacks Investment Research Medtronic’s upcoming fiscal first-quarter results are expected to reflect ongoing momentum in CAS, as well as strength in businesses such as Cardiac Rhythm Management and Cranial and Spinal Technologies. At the same time, the company is also advancing its M&A and venture initiatives, targeting higher-growth segments to accelerate innovation. While current indicators do not point to a strong earnings beat, the company has a consistent earnings surprise history, which is encouraging. Medtronic’s recent stock performance has been impressive, outpacing the key benchmarks and peers. Existing MDT shareholders should consider holding their positions, supported by the company’s attractive valuation. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report Boston Scientific Corporation (BSX) : Free Stock Analysis Report Edwards Lifesciences Corporation (EW) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research